Among the variables that characterize mechanical cardiac performance, left ventricular ejection fraction (LVEF) has attracted broad clinical interest, as various studies have provided ample evidence that LVEF is a major prognostic parameter [1][2][3][4]. Also, LVEF is among the selection criteria for device-based anti-arrhythmic or resynchronization therapy [5, 6]. Several imaging techniques allow for the assessment of LVEF, e.g., 2D and 3D echocardiography, gated SPECT, contrast angiography, cardiovascular magnetic resonance imaging (CMR) and computed tomography [7]). In patients with suspected ischemia, a common strategic sequence in which imaging techniques are being utilized is echocardiography, gated SPECT and coronary angiography, the latter frequently combined with or followed by intervention. As these three imaging techniques may all yield LVEF values it is not uncommon in clinical practice to have access to multiple LVEF measurements of the same patient.
Among the variables that characterize mechanical cardiac performance, left ventricular ejection fraction (LVEF) has attracted broad clinical interest, as various studies have provided ample evidence that LVEF is a major prognostic parameter [1] [2] [3] [4] . Also, LVEF is among the selection criteria for device-based anti-arrhythmic or resynchronization therapy [5, 6] . Several imaging techniques allow for the assessment of LVEF, e.g., 2D and 3D echocardiography, gated SPECT, contrast angiography, cardiovascular magnetic resonance imaging (CMR) and computed tomography [7] ). In patients with suspected ischemia, a common strategic sequence in which imaging techniques are being utilized is echocardiography, gated SPECT and coronary angiography, the latter frequently combined with or followed by intervention. As these three imaging techniques may all yield LVEF values it is not uncommon in clinical practice to have access to multiple LVEF measurements of the same patient.
If, in one patient, these three LVEF values are available, what would be the measure of preference? The answer to this question depends upon the reliability of the measurement technique and on its proven prognostic value. Whether or not the echocardiogram, gated SPECT and the ventriculogram determined during angiography faithfully assess LVEF depends on a large variety of factors: the build of the patient, the technical quality of the equipment, amount of views (monoplane/biplane), quality of the analyzing software/algorithms, the potential for quantitative analysis, and of the operator/analyst being the most important ones [8] [9] [10] [11] [12] [13] .
Comparison with CMR, an important reference technique often being considered as a gold standard [14] [15] [16] [17] [18] [19] [35] [36] [37] were reported. Hence, potentially, one measurement could bear other diagnostic and prognostic information than the other.
It is the merit of Gimelli et al. [38] to have compared the prognostic value of LVEF determined by echocardiography (single plane), gated SPECT and contrast ventriculography (single plane). The authors found, in a large population of patients with known or suspected ischemic heart disease, a superior predictive value of gated SPECT (resting, not postexercise) LVEF. What can explain this finding? It is well known that systematic differences exist because SPECT may exclude part of the outflow tract [36] . Also, it may well be that the single plane LVEF measurements in the echocardiograms and in the contrast ventriculograms could not compete with the tomographic gated SPECT technique. Finally, the SPECT LVEF calculation is more objective and reproducible due to automated analysis [39] .
Gimelli et al. studied a large group of 422 patients with for the larger part an adequate cardiac function.
Ejection fractions below, but also above 50%, the lower limit of normal in male subjects, are represented in the study group. Possibly (this was not made explicit in their publication), part of the patients had symptoms of overt, stage C, heart failure, but most of the other patients in the study group can be characterized as stage B heart failure (patients with structural heart disease, at risk for heart failure but still without symptoms of this disease [40] ), several of them with asymptomatic LV systolic dysfunction and angina pectoris/myocardial infarction.
In a review article [41] , Goldberg and Jessup state that the number of stage B heart failure patients with LV systolic dysfunction is four times greater than the number of patients who are in stages C (structural heart disease with prior or current symptoms of heart failure) and D (refractory heart failure requiring specialized interventions) combined. Coronary artery disease is the prevailing etiology of asymptomatic LV systolic dysfunction. In the Framingham study, half of the subjects with asymptomatic LV systolic dysfunction at entry had a previous myocardial infarction versus 2% of the subjects with a normal LV function at entry [42] . The prognosis of asymptomatic LV systolic dysfunction was unfavorable: 26% developed overt heart failure after 5 years of follow-up, and 40% died (compared to 12% of the subjects with a normal baseline left-ventricular function). The median survival for subjects with asymptomatic LV systolic dysfunction was only 7.1 years. Similarly alarming numbers were provided by the ECHOES (Echocardiographic Heart of England Screening) study [43] , reporting a 69% five-year survival for asymptomatic LV systolic dysfunction (compared to 93% for the general population, 62% for subjects with heart failure but without LV systolic dysfunction, and 53% for subjects with heart failure and LV systolic dysfunction).
No specific treatment is currently available for patients with asymptomatic LV systolic dysfunction. However, a recent AHA Scientific Statement [44] mentions this group of patients as a main target for further study, because LV systolic dysfunction is the first step in the remodeling process that finally leads to overt heart failure. Research recommendation 4 reads: ''Develop appropriate studies to identify and eventually treat asymptomatic individuals with LV dysfunction (stage B) and to prevent its development.'' Most likely, the findings of Gimelli et al. reflect partly the prognosis of stage B heart failure patients. Therefore, it could be worthwhile to carefully monitor patients for cardiac remodeling, possibly by repeated 3D echocardiography [23, 45] 
A similar study as that by Gimelli et al., in which, in this setting, the prognostic power additional to clinical variables of LVEF determined by gated SPECT is compared with LVEF determined by biplane echocardiography or contrast ventriculography or by 3D echocardiography would be a logical next step.
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